RGC - Regencell Bioscience Holdings Ltd
IEX Last Trade
7.93
0.710 8.953%
Share volume: 14,216
Last Updated: Fri 30 Aug 2024 03:46:28 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$7.22
0.71
9.83%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-11.51%
1 Month
-34.45%
3 Months
53.83%
6 Months
2.41%
1 Year
-52.43%
2 Year
-73.16%
Key data
Stock price
$7.93
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.03 - $21.00
52 WEEK CHANGE
-$0.51
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/24/2024
Company detail
CEO:
Region: US
Website: regencellbioscience.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: regencellbioscience.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
we are an early-stage bioscience company that focuses on research, development and commercialization of tcm for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder (“adhd”), autism spectrum disorder (“asd”) in infectious diseases such as covid-19. our goal is to improve the lives of adhd, asd and covid patients, their families and caregivers and become a market leader for the best tcm treatment globally.
Recent news